Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENOB Stock Price Chart Interactive Chart >
ENOB Price/Volume Stats
| Current price | $1.08 | 52-week high | $9.23 |
| Prev. close | $1.08 | 52-week low | $0.95 |
| Day low | $1.07 | Volume | 46,100 |
| Day high | $1.10 | Avg. volume | 42,422 |
| 50-day MA | $1.34 | Dividend yield | N/A |
| 200-day MA | $2.85 | Market Cap | 57.19M |
Enochian Biosciences, Inc. (ENOB) Company Bio
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
Latest ENOB News From Around the Web
Below are the latest news stories about ENOCHIAN BIOSCIENCES INC that investors may wish to consider to help them evaluate ENOB as an investment opportunity.
Enochian gets Nasdaq notice for delaying (NASDAQ:ENOB)Enochian BioSciences (ENOB) said Wednesday it received a notice from Nasdaq stating that the company has not yet filed its Form 10-Q for the period ended September 30, 2022, making… |
Enochian BioSciences, Inc.: Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("… |
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the |
Enochian BioSciences Forges Ahead With Focused Approach, Promising FutureLOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center. |
Enochian BioSciences, Inc.: Enochian BioSciences Forges Ahead With Focused Approach, Promising FutureLOS ANGELES, Oct. 24, 2022its oncology platform was awarded a U.S. patent and has produced promising early resultsin studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also a… |
ENOB Price Returns
| 1-mo | -6.09% |
| 3-mo | -49.06% |
| 6-mo | -53.04% |
| 1-year | -75.57% |
| 3-year | -76.77% |
| 5-year | -75.73% |
| YTD | 4.85% |
| 2022 | -85.87% |
| 2021 | 147.12% |
| 2020 | -41.24% |
| 2019 | -28.29% |
| 2018 | 47.37% |
Loading social stream, please wait...